Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can provide a promising source of midbrain dopaminergic (DA) neurons for cell replacement therapy for Parkinson's disease (PD). To evaluate safety and efficacy of the human ESC-derived DA neurons, we induced neural progenitor cells from human ESCs by a modified SDIA (stromal cell-derived inducing activity) method. When the cells were transplanted into the bilateral striatum of monkey models of PD, they did not form tumors and survived as DA neurons as long as 12 months proved by immunofluorescence and PET studies. In addition, the monkeys showed behavioral improvement after 3 months post-transplantation. We also generated DA neurons from human induced pluripotent stem cells (iPSCs) without feeder cells, and confirmed that these cells could survive as long as 6 months in the monkey brain. These results support the idea that human ESCs/iPSCs can be used as a source for cell replacement therapy of PD. However, ESC/iPSC-derived donor cells may inevitably contain tumorigenic or inappropriate cells. Therefore, as a next step, we have developed a method for 1) scalable DA neuron induction on human laminin fragment and 2) sorting DA progenitor cells using a floor plate marker. The sorting of DA progenitor cells is favorable in terms of both safety and efficacy of the transplantation, and we have now established a protocol for the clinical application of human iPSCs to treat Parkinson's disease.
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The term of 'humanized mouse' model have recently become popular since in the early 2000s, a series of immunodeficient mice such as NOG, NSG and BRG mice appropriate for generating humanized mice has been successively developed. These strains show not only a high rate of human cell engraftment but also generate well-differentiated multi-lineage human hematopoietic cells after human hematopoietic stem cell (HSC) transplantation. Humanize mouse models are extremely useful for the study of mechanisms underlying various human disease and in drug development. Various human disease mouse models using these humanized mice have been actually developed. However, human hematopoietic cells developed from HSCs are not always phenotypically and functionally identical to those in humans. To overcome these disadvantages, development of a new series of immunodeficient mice has been attempted by genetically introducing human cytokine genes into NOG mice. Our institute, CIEA has a long history for development of immunodeficient mice. The history started from 1973 when Dr. Tatsuji Nomura, the late director of CIEA, introduced nude mice from Dr. Friis of Denmark. In this presentation, I will talk on the history to NOG mice, and the resulting NOG and the further improved immunodeficient mice and their application as humanized models, and also discuss on what strategies to pursue more appropriate humanized mouse models. Finally, I sincerely express my gratitude to Dr. Nomura for his forethought, enthusiasm and guide on these studies. Laboratory animals such as mice and rats have contributed greatly to understanding the mechanisms of human diseases and the development of therapeutic reagents and regimens. The emergence of genome editing technologies with ZFNs, TALENs, and CRISPR/Cas allows simple generation of genetically-modified animals and is dramatically accelerating the production of new models for functional genomics and human diseases in a variety of species. We employed the CRISPR/Cas9 system as an accurate and efficient genome editing tool in rats. Microinjection of guide RNA and Cas9 mRNA into rat embryos induced a variety of insertion and deletion mutations and efficiently generated knockout rats. Co-injection of single-stranded oligodeoxyribonucleotide and CRISPR components enabled us to generate several types of targeted knock-in rats, such as single nucleotide polymorphism substitution, short DNA fragment integration, and large DNA fragment elimination (Yoshimi K et al., Nat Commun, 5:4240, 2014) . Furthermore, we recently established a simple methodology to introduce longer DNA fragments into the targeted genome sequences. This knock-in technology is applicable to any target site with any donor vector in any strain or species. The CRISPR/Cas9 system is an efficient genome editing tool to generate genetically-modified animals. Application of these genome-editing techniques will dramatically accelerate the biomedical researches, such as advanced medical studies, drug design, and regenerative medicine. Combination with excellent phenotyping will also greatly improve our understanding of gene functions and gene regulatory networks in physiological, pharmacological, biochemical and behavioral systems.
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Mice harboring large segments of human chromosomes are very important tools for generating human disease models, as well as for biomedical applications. Yeast artificial chromosomes (YACs) and bacterial artificial chromosomes (BACs) were first utilized for the generation of mice containing large human genomic fragments. However, BACs, and YACs have a cloning capacity of 300 kb and 1 -2Mb, respectively. Transchromosomic (Tc) technology using human chromosome fragments (hCFs) has been utilized for generating mice containing human Mb-sized segments. However, germ line transmission was limited using the hCFs, due to the large number of human genes introduced. We therefore generated a minimal human artificial chromosome (HAC) vector from human chromosome 21 and developed a HAC-mediated genomic transfer (HMGT) system. However, the most significant problem with freely segregating chromosomes with human centromeres has been mosaicism, possibly due to the instability of hCFs or HACs in mice. To overcome this problem, we developed novel two systems for the stable maintenance of large human genomic regions in mice. In one approach, we established a new strategy for the stable maintenance of the human regions following translocation to mouse chromosome 10 terminal region. In the other approach, we constructed novel mouse artificial chromosome (MAC) vectors from a native mouse chromosome and cloned the human regions into the MAC. In the both approaches, the Mb-sized human regions were germline-transmittable and stably maintained in mice, and human genes from the regions were functionally expressed in mice. Thus, newly developed Tc technology will be useful for studying in vivo functions of the human genomic regions, and generating humanized model animals.
